Takeda Pharmaceutical Company Limited Earnings

Takeda Pharmaceutical Company Limited’s revenue jumped 0.24% since last year same period to $1053399Mn in the Q1 2025. On a quarterly growth basis, Takeda Pharmaceutical Company Limited has generated -7.93% fall in its revenue since last 3-months.

Takeda Pharmaceutical Company Limited’s net profit fell -3317.99% since last year same period to $-103155Mn in the Q1 2025. On a quarterly growth basis, Takeda Pharmaceutical Company Limited has generated -533.62% fall in its net profits since last 3-months.

Takeda Pharmaceutical Company Limited’s net profit margin fell -3309.78% since last year same period to -9.79% in the Q1 2025. On a quarterly growth basis, Takeda Pharmaceutical Company Limited has generated -570.97% fall in its net profit margins since last 3-months.

Takeda Pharmaceutical Company Limited’s price-to-earnings ratio after this Q1 2025 earnings stands at 67.04.

Takeda Pharmaceutical Company Limited’s earning per share (EPS) estimates for the current quarter stand at 0.2 - a 220.84% jump from last quarter’s estimates.

Takeda Pharmaceutical Company Limited’s earning per share (EPS) estimates for the current year stand at 0.2.

Takeda Pharmaceutical Company Limited’s earning per share (EPS) fell -3401.54% since last year same period to -0.23 in the Q1 2025. This indicates that the Takeda Pharmaceutical Company Limited has generated -3401.54% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Takeda Pharmaceutical Company Limited’s return on assets (ROA) stands at 0.02.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Takeda Pharmaceutical Company Limited’s return on equity (ROE) stands at 0.02.